Aiforia joins the EU-funded Thera4Care project to advance precision medicine
Aiforia Technologies Plc, Press Release, October 7, 2024 at 04:15 p.m. EEST
Aiforia joins the EU-funded Thera4Care project to advance precision medicine
Aiforia Technologies is one of the industry partners to join the recently launched Thera4Care project – Theranostics Ecosystem For Personalised Care. This project, funded by Innovative Health Initiative Joint Undertaking (IHI JU), an EU public-private partnership funding health research and innovation, gathers 29 partners from top European academic and clinical sites, small and medium-sized enterprises, and patient advocacy groups. Aiforia, the only company in the consortium focusing on digital pathology AI solutions, has been granted 300,000 euros in funding to support the development of robust AI solutions for clinical decision support and predictive modeling to enable personalized medicine.
The Thera4Care project runs for the next five years and aims to revolutionize precision oncology and establish Europe as a global leader in theranostics. Theranostics combines diagnostic tests with targeted therapies, enabling personalized treatments. The project aims to create a collaborative European ecosystem to support healthcare system readiness for theranostics.
“We are proud to be a part of the Thera4Care project. By developing cutting-edge AI solutions for clinical decision support, Aiforia is committed to advancing personalized patient care. This initiative represents an exciting opportunity for Europe to lead the way in precision oncology, and we are happy to collaborate with world-class partners to make this vision a reality,” says Jukka Tapaninen, CEO of Aiforia.
For more information, read the press release by the project’s industrial lead GE Healthcare, and visit the project website.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com